2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-117610
    Ro 31-8830 131848-98-1 98%
    Ro 31-8830 is an orally active, potent and selective inhibitor of protein kinase C with anti-inflammatory activity. Ro 31-8830 is promising for research of inflammatory disorders.
    Ro 31-8830
  • HY-117622
    ND-2110 1388894-17-4 98%
    ND-2110 is a selective IRAK4 inhibitor (Ki: 7.5 nM). ND-2110 binds to the ATP pocket of IRAK4. ND-2110 targets the subset of activated B cell-like (ABC) subtype of diffuse large B cell lymphoma (DLBCL) cell lines with MYD88 L265P mutations,. ND-2110 inhibits LPS-induced TNF production, alleviates collagen-induced arthritis, and blocks gout formation in mouse models.
    ND-2110
  • HY-117657
    (-)-BO 2367 145902-81-4 98%
    (-)-BO 2367, an antimicrobial quinolone, is a strong mammalian and bacterial topoisomerase II inhibitor. (-)-BO 2367 shows IC50 values with 3.8 μM, 0.5 μM, and 1 μM against the DNA relaxation activity of L1210 topoisomerase II and the supercoiling activities of Escherichia coli gyrase and Micrococcus luteus gyrase, respectively. (-)-BO 2367 is a potent antitumor agent.
    (-)-BO 2367
  • HY-117706
    LY 292728 153034-77-6 98%
    LY 292728 is a potent leukotriene B4 (LTB4) receptor antagonist. LY 292728 binds to human neutrophils with a Ki of 0.47 nM and binds to guinea pig lung membranes with a Ki of 0.04 nM.
    LY 292728
  • HY-117784
    BI-L-357 149539-02-6 98%
    BI-L-357 is a succinate derived from BI-L-226 that acts as a precursor, enhances oral bioavailability and inhibits 5-lipoxygenase-mediated leukotriene production.
    BI-L-357
  • HY-117826
    JNJ 28610244 1251462-28-8 98%
    JNJ 28610244 is a H4R agonist, with a pKi of 7.3 and pEC50 of 7.0, respectively.
    JNJ 28610244
  • HY-117854
    SB 201146 141311-11-7 98%
    SB 201146 is an LTB4 receptor antagonist with a potency range of 10 pM to 1 μM that plays a critical role in asthma-associated airway inflammation. Studies have focused on its effects on eosinophil survival, a hallmark of asthma pathology. Studies have shown that eosinophil-derived cysteinyl leukotrienes, including LTC4 and LTD4, as well as factors such as GM-CSF and fibronectin promote eosinophil survival. SB 201146 effectively reversed mast cell- and lymphocyte-induced eosinophil survival, highlighting its potential therapeutic role in disrupting the autocrine cysteinyl leukotriene pathway that maintains eosinophil viability. This antagonist also highlights the importance of LTB4 as a paracrine mediator that influences eosinophil survival in inflammatory settings such as asthma.
    SB 201146
  • HY-117862
    TASP0412098 1233248-29-7 98%
    TASP0412098 is an orally available, potent and selective CRTH2/DP2 antagonist with high binding affinity (IC50 2.1 nM) and functional activity (IC50 12 nM). TASP0412098 has the potential to suppress asthma in mouse and guinea pig bronchial asthma models.
    TASP0412098
  • HY-117918
    ST-1892 1409411-32-0 98%
    ST-1892 (compound 14) is a highly potent FXR agonist (EC50=7.2 nM) that can be used to study diseases or disorders caused by metabolic inflammation.
    ST-1892
  • HY-117981
    OUP-186 1480830-24-7 98%
    OUP-186 is a histamine H3 receptor antagonist.
    OUP-186
  • HY-118086
    MRS1067 70460-45-6 98%
    MRS 1067 is a competitive antagonist of the adenosine A3 receptor that inhibits the suppression of adenylate cyclase by adenosine A3 receptor agonists and affects the activation of G proteins. MRS 1067 can be used in research related to inflammation and cancer.
    MRS1067
  • HY-118133
    4'-Hydroxy flurbiprofen 52807-12-2 98%
    4'-Hydroxy flurbiprofen is an oxidative metabolite of Flurbiprofen (HY-10582) via the cytochrome P450 enzyme system. 4'-Hydroxy flurbiprofen inhibits COX-1 by 94% at a concentration of 1000 µM.
    4'-Hydroxy flurbiprofen
  • HY-118177
    Neutrophil elastase inhibitor 1 1448314-31-5 98%
    Neutrophil elastase inhibitor 1 (Compound 5b) is a competitive, pseudoirreversible inhibitor for neutrophil elastase with an IC50 of 7 nM.
    Neutrophil elastase inhibitor 1
  • HY-118261
    L 659286 119742-06-2 98%
    L 659286 is an inhibitor of human polymorphonuclear leukocyte elastase (PMN elastase) (Ki=0.4 μM). Intratracheal injection of L 659286 can induce lung injury in hamsters.
    L 659286
  • HY-118312
    CAY10657 494772-86-0 98%
    CAY10657 is an inhibitor for NF-κB pathway. CAY10657 downregulates expressions of proinflammatory cytokine (IL-6) and chemokine (MCP-1), and thus exhibits anti-inflammatory efficacy against meningitis induced by Streptococcus suis.
    CAY10657
  • HY-118315
    L-012 143323-55-1 98%
    L-012 is a luminal-based chemiluminescent probe. L-012 sodium salt can detect NADPH oxidase (Nox)-derived superoxide and nitrogen species (reactive oxygen species (ROS) and reactive nitrogen species (RNS)).
    L-012
  • HY-118370
    MF-592 1064195-48-7 98%
    MF-592 is an inhibitor of PGE2 (IC50=3 nM) and exhibits good oral PK properties in rats and dogs.
    MF-592
  • HY-118374
    AM-9635 1338483-10-5 98%
    AM-9635 is a selective PI3Kδ inhibitor with oral bioavailability, good in vitro and in vivo activity and pharmacodynamic properties. AM-9635 inhibits PI3Kδ-dependent B cell receptor-mediated AKT phosphorylation and suppresses the production of specific IgG and IgM antibodies in rats immunized with Aplysia leocyanin (KLH).
    AM-9635
  • HY-118379
    NU/ICRF 500 156074-08-7 98%
    NU/ICRF 500 is a topo II catalytic inhibitor which increases CREST negative micronuclei in human lymphocytes.
    NU/ICRF 500
  • HY-118403
    CK2-IN-12 300675-28-9 98%
    CK2-IN-12 (Compound 39) is an inhibitor for protein kinase CK2 with an IC50 of 0.8 μM.
    CK2-IN-12
Cat. No. Product Name / Synonyms Application Reactivity